Editas Medicine's layoffs represent a critical pivot toward optimizing its cost structure, as the company refocuses entirely on in vivo gene editing.
President and CEO stated, 'Two years ago, we laid out our strategy and objective to become a leader in in vivo programmable gene editing... we are transitioning to a fully in vivo company.'
O'Neill expressed gratitude to patients and staff, saying, 'We want to extend our deepest appreciation...We are even more committed to accelerating our efforts towards an in vivo program for sickle cell disease and beta thalassemia.'
Collection
[
|
...
]